Effect and mechanism of the miR-1284/EIF4A1 axis on the cGAS-STING pathway under radiotherapy

Wenlong Cao1, Ka Su1, Chunmiao Lu2

  • 1Department of Gastrointestine and Gland Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.

PubMed
Abstract

Insights

MicroRNA-1284 (miR-1284) and eukaryotic translation initiation factor 4A1 (EIF4A1) promote gastric cancer cell survival by aiding DNA repair after radiotherapy. Blocking this axis enhances treatment efficacy and anti-tumor immunity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Gastric cancer (GC) presents significant global health challenges, with limited therapeutic options for advanced stages.
  • Radiotherapy (RT) is crucial for GC management, but resistance to DNA damage limits its effectiveness.
  • The microRNA-1284 (miR-1284)/eukaryotic translation initiation factor 4A1 (EIF4A1) axis influences DNA damage repair and GC cell survival post-RT.

Purpose of the Study:

  • To investigate the role of the miR-1284/EIF4A1 axis in DNA repair and its impact on the cGAS-STING pathway in GC under RT.
  • To explore how this axis influences the anti-tumor immune response and RT efficacy in GC.
  • To evaluate the potential of targeting this axis for improved GC treatment.

Main Methods:

  • Establishment of a stably expressed miR-1284 cell line in GC.
  • Quantitative reverse transcription and western blot to assess miR-1284 and EIF4A1 expression.
  • Cytotoxicity and in vivo animal experiments to evaluate therapeutic strategies.

Main Results:

  • The miR-1284/EIF4A1 axis promotes radiation-induced DNA damage repair and is linked to GC patient prognosis.
  • Blocking this axis impairs C-terminal binding protein interacting protein (CtIP)-mediated DNA repair, enhancing RT effectiveness and apoptosis.
  • The miR-1284/EIF4A1 axis activates the cGAS-STING pathway, contributing to anti-tumor immunity.

Conclusions:

  • The miR-1284/EIF4A1 axis enhances RT efficacy in GC by promoting DNA repair and activating the cGAS-STING pathway.
  • Targeting this axis offers a promising strategy to improve RT's anti-tumor immune effects in GC treatment.
  • Combined therapy with rocaglamide and PD-L1 antibodies shows good biological safety and potential for GC treatment.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.0K